Source: Annual Congress 2012 - Exacerbations of asthma and COPD: assessment, impact and novel treatments
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
G.J. Braunstahl, A. Georgiou, J. Canvin, R. Maykut, J. Bruce, C.W. Chen (Rotterdam, Netherlands; Nycosia, Cyprus; Horsham, United Kingdom; Basel, Switzerland; East Hanover, United States Of America). Reductions in exacerbations with omalizumab in a real-world setting. Eur Respir J 2012; 40: Suppl. 56, 198

Member's Comments

No comment yet.

Related content which might interest you: Omalizumab decreases medical resource utilisation in patients with severe allergic asthma in an Italian real-life setting Source: International Congress 2017 – Asthma management Year: 2017 Physician assessment of asthma control in patients receiving omalizumab in a real-world setting Source: Annual Congress 2012 - Asthma treatment: efficacy and safety Year: 2012 Anti-IgE therapy with omalizumab decreases exacerbations in patients with poorly controlled moderate-to-severe allergic asthma Source: Eur Respir J 2003; 22: Suppl. 45, 203s Year: 2003 The cost-effectiveness of azithromycin in reducing exacerbations in uncontrolled asthma Source: Eur Respir J, 57 (2) 2002436; 10.1183/13993003.02436-2020 Year: 2021 Ceruloplasmine efficacy in patients with asthma exacerbations Source: Annual Congress 2011 - Novel mechanisms in lung injury Year: 2011 Budesonide/formoterol for the treatment of COPD exacerbations in the primary healthcare setting Source: Annual Congress 2008 - Pathogenesis and treatment of asthma and COPD Year: 2008 Patients’ perception of allergic asthma and their compliance to omalizumab in an Italian clinical setting Source: International Congress 2017 – Asthma management Year: 2017 Control of persistent asthma patients on inhaled corticosteroids in a real-life setting Source: Annual Congress 2010 - New insights in the epidemiology of asthma Year: 2010 Evaluating the efficacy of omalizumab in severe persistent asthma patients Source: International Congress 2017 – Evolution or revolution in the treatment of asthma and allergies Year: 2017 Could montelukast reduce asthma exacerbations? Source: Annual Congress 2008 - Advances in the treatment and pathogenesis of pulmonary diseases Year: 2008 Analysis of two-year treatment with omalizumab patients with severe asthma in real clinical practice Source: International Congress 2019 – Real-world experience of monoclonal antibodies in asthma Year: 2019 Real-life long-term omalizumab therapy in children with severe allergic asthma Source: Eur Respir J 2015; 46: 856-859 Year: 2015 Severe asthma and biologic therapies during COVID-19: supporting patients care with home administration of mepolizumab and omalizumab Source: Virtual Congress 2021 – Asthma clinical trials and real-life studies Year: 2021 Budesonide/formoterol added to tiotropium improves exacerbations and exacerbation-related antibiotic use in patients with COPD Source: Annual Congress 2009 - Drug effects in COPD Year: 2009 Real-life effectiveness of omalizumab in patients with severe persistent allergic asthma: the PERSIST study Source: Annual Congress 2009 - Towards improving asthma control Year: 2009 Utility of high dose inhaled fluticasone therapy for the early management of acute exacerbations of asthma Source: Annual Congress 2009 - Next generation bronchodilators Year: 2009 The use of omalizumab in the management of severe chronic paediatric asthma Source: Annual Congress 2008 - Drug therapy and assessment of control in childhood asthma Year: 2008 Utility of aerosolized budesonide therapy in acute moderate exacerbations of asthma Source: Eur Respir J 2003; 22: Suppl. 45, 283s Year: 2003 Predictors of effectiveness of omalizumab treatment in patients with severe asthma recruited in a real-life setting Source: International Congress 2015 – New data on established treatments for asthma and COPD Year: 2015 Cost effectiveness of omalizumab in Swedish asthma patients Source: Eur Respir J 2006; 28: Suppl. 50, 441s Year: 2006